Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SI-B036-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B036 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies

NCT07857616 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT07857616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07857616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SI-B036-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B036 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2029
Enrollment
424 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced / metastatic solid tumors, locally advanced /metastatic solid tumors, lung cancer, melanoma, metastatic solid cancers, non small cell lung cancer, nsclc, ovarian